Aquestive Therapeutics, Inc. (AQST) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A reveal strong financial performance, strategic product development, and promising market strategies. Anaphylm's launch preparation and international expansion plans are positive indicators, supported by stable financials and a robust cash position. The Q&A highlights management's proactive approach to market challenges and confidence in regulatory timelines, despite some uncertainties. Overall, the company's strategic initiatives and financial health suggest a positive stock price movement.
Key Financial Performance
Total Revenues $14.4 million in Q1 2026, a 66% increase from $8.7 million in Q1 2025. The increase was primarily driven by higher license and royalty revenue and manufacturing and supply revenue.
License and Royalty Revenue $5.4 million in Q1 2026, up from $0.8 million in Q1 2025. The increase was primarily due to the recognition of royalty revenue from Zevra.
Manufacturing and Supply Revenue $8.8 million in Q1 2026, up from $7.2 million in Q1 2025. The increase was primarily due to higher Suboxone revenues, partially offset by lower Ondif revenues.
Research and Development Expenses $4.2 million in Q1 2026, down from $5.4 million in Q1 2025. The decrease was primarily due to lower clinical trial costs associated with the Anaphylm development program, partially offset by increases in R&D personnel costs.
Selling, General and Administrative Expenses $11 million in Q1 2026, down from $19.1 million in Q1 2025. The decrease was primarily due to a one-time Anaphylm PDUFA fee in the prior year, lower legal fees, lower commercial spending, and lower regulatory and licensing fees, partially offset by higher severance costs, personnel costs, and share-based compensation expenses.
Net Loss $8.1 million in Q1 2026, compared to $22.9 million in Q1 2025. The decrease was driven by higher revenues, lower selling, general and administrative expenses, and lower research and development expenses, partially offset by decreases in interest income and other income net.
Non-GAAP Adjusted EBITDA Loss $1.7 million in Q1 2026, compared to $17.6 million in Q1 2025. The improvement was due to higher revenues and lower expenses.
Cash and Cash Equivalents Approximately $110 million at the end of Q1 2026. This cash position supports ongoing operations, regulatory planning, and potential commercial launch preparations.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Anaphylm (dibutepinephrine sublingual film): Completed Type A meeting with FDA, teleconference with MHRA, submitted pediatric investigational plan to EMA, and human factors protocol to FDA. Phase I safety study completed for AQST-108. Human factors and pharmacokinetic data expected by August earnings call. Resubmission to FDA planned for Q3 2026.
AQST-108: Phase I safety study completed with no drug-related adverse events. Preliminary data suggests potential impact on cytokine TSLP, relevant for dermatological conditions like alopecia areata and atopic dermatitis.
U.S. Market: Commercial preparations for Anaphylm include a 75-person sales force, strong medical affairs presence, and focused marketing. Plans to build awareness and access within the allergy community.
International Market: Progress in Canada, U.K., and EU regulatory processes. Applications can be submitted without additional clinical studies. Potential market reach of 1 billion people if approved in U.S., Canada, U.K., and EU.
Debt Facility: Secured $150 million debt facility with Oaktree, improving interest rate terms and extending principal payment timeline. Provides additional $20 million upon FDA approval of Anaphylm.
Revenue Growth: Q1 2026 revenue increased by 66% to $14.4 million compared to Q1 2025, driven by license, royalty, and manufacturing revenues.
Cost Management: Reduced R&D and SG&A expenses, leading to a net loss reduction from $22.9 million in Q1 2025 to $8.1 million in Q1 2026.
Regulatory Strategy: Focused on expediting FDA review for Anaphylm and aligning with international regulatory bodies to expand market reach.
Pipeline Development: Advancing AdrenaVerse platform and AQST-108 for potential multiple indications. Business development efforts ongoing in Europe, U.S., South America, China, and Australia.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approval Challenges: The company's progress with Anaphylm is contingent on timely and constructive feedback from the FDA regarding the human factors protocol and pharmacokinetic data. Delays or unexpected feedback from the FDA could impact the resubmission timeline and subsequent approval process.
Debt and Financial Flexibility: While the company has secured a $150 million debt facility, the financial health and flexibility are tied to achieving regulatory and sales milestones. Failure to meet these milestones could limit access to additional funding tranches and strain liquidity.
Market Launch Risks: The success of Anaphylm's launch depends on building trust and awareness within the allergy community. Failure to effectively engage allergists and integrate into their practices could hinder prescription uptake and market penetration.
International Regulatory and Market Entry: Although progress has been made in the U.K., EU, and Canada, the company must align with multiple regulatory bodies and navigate complex approval processes. Any misalignment or delays could impact international market entry.
Pipeline Development Risks: The AQST-108 program is in early stages, and while initial data is promising, further studies are required to confirm efficacy and safety. Any setbacks in development could delay or derail the program.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Anaphylm FDA Resubmission: Aquestive expects to have human factors data and potentially pharmacokinetic data for Anaphylm available by the August 2026 earnings call. The company plans to resubmit the NDA for Anaphylm to the FDA in the third quarter of 2026, with a potential six-month review period. They will request expedited review upon submission, though the final decision on timing rests with the FDA.
Commercial Launch Preparations for Anaphylm: Aquestive is preparing for the potential U.S. launch of Anaphylm, including plans for a 75-person sales force, a strong medical affairs presence, and focused marketing efforts. The company aims to build trust and support within the allergy community to drive prescriptions.
International Expansion for Anaphylm: Aquestive plans to submit regulatory applications for Anaphylm in Canada, the U.K., and the European Union without conducting additional clinical studies. If approved in these regions, the product could be available to nearly 1 billion people globally in the coming years.
Pipeline Development - AQST-108: Aquestive completed a Phase I safety study for AQST-108, showing no drug-related adverse events and promising early data on its impact on biomarkers associated with dermatological conditions. Further studies are planned after the Anaphylm resubmission.
Financial Guidance for 2026: Aquestive projects total revenue of $46 million to $50 million and a non-GAAP adjusted EBITDA loss of $35 million to $30 million for 2026. The company expects to have over $150 million in cash at the launch of Anaphylm, supported by a $150 million debt facility and other funding agreements.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide more details on the preparation for the U.S. filing and ongoing study interactions for Anaphylm?
A:The company is ready to proceed with the studies for Anaphylm. The study designs are complete, sites are prepared, and the only pending step is the FDA's review of the human factors protocol, expected in the next few weeks. Once approved, studies will commence.
Q:How does the biomarker data for AQST-108 compare to other programs targeting similar indications?
A:The biomarker data for AQST-108 shows promise, particularly in dermatology, as it crosses Th1 and Th2-driven inflammation pathways. This provides potential for applications in alopecia areata, androgenic alopecia, and atopic dermatitis. The data is directional and confirms the program's potential in the dermatologic space.
Q:What gives you confidence in achieving coverage and reimbursement for Anaphylm?
A:The company acknowledges that coverage and reimbursement are challenging for all life sciences companies. They are working on foundational efforts, including robust discussions with PBMs and payers, setting up a best-in-class hub, and patient support services to reduce friction for physicians and patients. However, they emphasize that achieving coverage will take time.
Q:What is the strategy for increasing awareness of Anaphylm?
A:The company has been actively participating in conferences (40 planned for the year) and publishing extensively (20 publications). They are engaging with healthcare professionals to build awareness and confidence in the product. Awareness among HCPs has increased from 33% to 66% due to these efforts.
Q:What are the learnings from the Neffy launch that are influencing your commercialization strategy for Anaphylm?
A:The key learning is that even innovative products require extensive groundwork, including engaging with doctors, telling the product story, and securing coverage. The company is focusing on reducing friction in physicians' offices, increasing awareness, and ensuring physicians believe in the product through scientific publications and real-world experience programs.
Q:How are you addressing friction in physicians' offices for Anaphylm?
A:The company is working on reducing friction through robust discussions with PBMs and payers, setting up a best-in-class hub, and support services. They are also tailoring their approach to address specific challenges in different practices but are keeping some strategies confidential.
Q:What is the status of FDA interactions and the timeline for Anaphylm?
A:The FDA review team remains stable, and the company expects a 6-month review clock for the Anaphylm submission. They are pushing for a faster review, citing the limited package being submitted. The submission is planned for Q3, with approval potentially in early 2024.
Q:What is the status of ex-U.S. filings for Anaphylm?
A:The company plans to file for regulatory approval in Canada and Europe by late 2026 or early 2027. They have met with regulatory bodies in these regions and believe the existing clinical package is sufficient for filings.
Q:What is the significance of the TSLP biomarker data for AQST-108?
A:The TSLP biomarker data is an exciting first step, showing potential for broad-based immunomodulation in dermatology. The data is directional and confirms the potential of AQST-108 in addressing inflammatory conditions. Further studies will explore this potential.
Q:What is the financial position of the company following the Oaktree financing?
A:The Oaktree financing, along with RTW support, provides the company with sufficient runway through the launch of Anaphylm, if approved. The company is in its best capital position to date and is confident in its financial readiness for the launch.
Q:What is the status of the Zevra royalty payment?
A:The $5.4 million received in Q1 includes a one-time payment from Zevra's sale of Azstarys. This amount is not indicative of a run rate for the year.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on how they plan to address friction in physicians' offices, stating that they would keep parts of their strategy confidential. Additionally, while they expressed confidence in the FDA review timeline, they did not provide concrete evidence or guarantees for an accelerated review beyond the standard 6-month period.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Aquestive website
Chief Development
Development Officer
EMA
Ernie
European Medicines
European Union
FDA review
JAK
MHRA UK
Medicines Agency
Officer Dr
Phase safety
RTW
TSLP
UK body
agency
areata
deal cash
debt facility
debt provider
epinephrine prodrug
face
factor
feedback review
life debt
mind
plan European
region
response
resubmission
review process
safety study
subject
AQST Transcript
Aquestive Therapeutics, Inc. (AQST) Q1 2026 Earnings Call Transcript
Positive5-14
The earnings call summary and Q&A reveal strong financial performance, strategic product development, and promising market strategies. Anaphylm's launch preparation and international expansion plans are positive indicators, supported by stable financials and a robust cash position. The Q&A highlights management's proactive approach to market challenges and confidence in regulatory timelines, despite some uncertainties. Overall, the company's strategic initiatives and financial health suggest a positive stock price movement.
Aquestive Therapeutics, Inc. (AQST) Q4 2025 Earnings Call Transcript
Unknown3-5
The earnings call presents a mixed outlook. The FDA approval and launch of Anaphylm, along with international expansion plans, suggest potential growth. However, financial guidance shows a significant EBITDA loss, and there are uncertainties regarding FDA meetings and protocol modifications. The Q&A reveals positive sentiment from the allergist community and readiness for regulatory requirements, but management's vague responses on certain issues raise concerns. Overall, the combination of positive development plans and financial challenges results in a neutral sentiment.
Aquestive Therapeutics, Inc. (AQST) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call summary presents a mixed outlook. Positive aspects include the FDA approval track for Anaphylm, international expansion plans, and new patents. However, financial guidance indicates a significant EBITDA loss, and management was vague on pricing and partnerships. The Q&A revealed cautious optimism but also highlighted uncertainties, such as pricing and international strategies. Considering these factors, the overall sentiment is neutral, anticipating limited stock price movement.
Aquestive Therapeutics, Inc. (AQST) Q2 2025 Earnings Call Transcript
Unknown8-12
The earnings call reveals a decline in revenue, increased expenses, and a substantial net loss, which are negative indicators. The Q&A session highlights uncertainties regarding FDA approval and payer engagement, further dampening sentiment. Despite robust clinical data, the lack of clear guidance on coverage and the need for additional funding for a full-scale launch contribute to a negative outlook. The absence of a new partnership announcement or positive financial metrics, coupled with the increased net loss and EBITDA loss, supports a negative stock price reaction.
AQST Slides
AQST Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
